Also known as MK-8591.
DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
DOR/ISL shows non-inferiority to BIC/FTC/TAF in HIV-1 treatment-naïve adults, meeting efficacy and safety goals. Detailed findings to be presented at a future scientific congress.
Phase 3 trials show minimal weight, body composition, and lipid changes with the DOR/ISL regimen in HIV-1 patients, maintaining viral suppression without resistance.
